GJD2

Across TCGA pan-cancer cohorts, GJD2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GJD2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher GJD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GJD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, BRCA, and SARC are the cancer types where GJD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.137	0.345	.006	15	view →
BRCA	DFS	Median	All	0.152	0.526	.034	8	view →
SARC	DFS	Median	All	0.200	0.614	.009	6	view →
UCEC	DFS	Median	All	1.000	0.635	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GJD2–SKCM (OS)

Open the SKCM breakdown →